Deutsche Bank AG Grows Stock Position in LifeStance Health Group, Inc. (NASDAQ:LFST)

Deutsche Bank AG increased its holdings in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 78.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 120,163 shares of the company's stock after buying an additional 52,970 shares during the quarter. Deutsche Bank AG's holdings in LifeStance Health Group were worth $886,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. increased its position in LifeStance Health Group by 124.4% in the fourth quarter. Blue Trust Inc. now owns 3,828 shares of the company's stock worth $27,000 after purchasing an additional 2,122 shares during the last quarter. LPL Financial LLC lifted its stake in LifeStance Health Group by 6.0% in the fourth quarter. LPL Financial LLC now owns 37,584 shares of the company's stock worth $277,000 after acquiring an additional 2,127 shares during the period. MetLife Investment Management LLC raised its holdings in LifeStance Health Group by 6.8% in the fourth quarter. MetLife Investment Management LLC now owns 85,914 shares of the company's stock worth $633,000 after purchasing an additional 5,492 shares in the last quarter. Legal & General Group Plc raised its holdings in LifeStance Health Group by 4.6% in the fourth quarter. Legal & General Group Plc now owns 134,557 shares of the company's stock worth $992,000 after purchasing an additional 5,917 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in LifeStance Health Group by 4.5% in the fourth quarter. Rhumbline Advisers now owns 195,581 shares of the company's stock worth $1,441,000 after purchasing an additional 8,487 shares in the last quarter. Institutional investors own 85.50% of the company's stock.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, insider Lisa K. Miller sold 18,845 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.90, for a total value of $130,030.50. Following the completion of the sale, the insider now owns 339,810 shares in the company, valued at approximately $2,344,689. The trade was a 5.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.20% of the stock is owned by company insiders.

LifeStance Health Group Stock Up 0.7%

LFST traded up $0.04 on Friday, reaching $5.95. The company's stock had a trading volume of 1,492,548 shares, compared to its average volume of 1,591,819. The stock has a 50 day moving average of $6.32 and a two-hundred day moving average of $7.12. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of -22.88 and a beta of 1.30. LifeStance Health Group, Inc. has a fifty-two week low of $4.64 and a fifty-two week high of $8.61.

Analyst Upgrades and Downgrades

LFST has been the topic of several recent analyst reports. Canaccord Genuity Group initiated coverage on shares of LifeStance Health Group in a report on Thursday, April 3rd. They set a "buy" rating and a $8.00 price objective on the stock. UBS Group raised shares of LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 price target on the stock in a research note on Tuesday. William Blair restated an "outperform" rating on shares of LifeStance Health Group in a report on Friday, February 28th. Finally, KeyCorp assumed coverage on LifeStance Health Group in a report on Tuesday, April 8th. They set an "overweight" rating and a $9.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, LifeStance Health Group has a consensus rating of "Moderate Buy" and an average price target of $8.50.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.